In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Haisco Pharmaceutical Group

Latest From Haisco Pharmaceutical Group

AbbVie U-Turns On Dong-A’s MerTK Program After Development Delays

After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.

South Korea Deals

FDA Greenlights Historical Control In Trial Of Regentis' GelrinC Knee Repair Material

The pivotal clinical study will support a US pre-market approval to allow Regentis Biomaterials to market GelrinC for the repair of focal knee cartilage defects in the knee, the largest unmet need in orthopedic sports medicine, according to the company.

Orthopedics Clinical Trials

Deals Shaping the Medical Industry, April 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2016.

BioPharmaceutical Medical Device

NICE Alzheimer’s decision a triumph for scientific reason

The publication by the UK health technology assessment body NICE (the National Institute for Health and Clinical Excellence) of draft guidance recommending the use of three acetylcholinesterase inhibitors in patients with mild to moderate Alzheimer’s disease, and an NMDA antagonist in patients with more advanced disease, has been widely welcomed as a “courageous decision” and as a “U-turn” on its previous guidance (, 7 October 2010).

See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Xizang Haisco Pharmaceutical Group Co.
    • Ltd, Hong Kong Haisco Pharmaceutical Co., Ltd
    • Sichuan Haisco Pharmaceutical Co., Ltd
    • Liaoning Haisco Pharmaceutical Co., Ltd
    • Huludao Xintianweng Pharmaceutical Co., Ltd
    • Chengdu Kangxin medical development Co., Ltd
    • Xizang Haisco biological technology co., Ltd.